Genetically driven CD39 expression shapes human tumor‐infiltrating CD8 + T‐cell functions

IL-27 confers a protumorigenic activity of regulatory T cells via CD39

(2019) Young-Jun Park et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Counter-regulation of regulatory T cells by autoreactive CD8+ T cells in rheumatoid arthritis

(2019) Ilenia Cammarata et al.   JOURNAL OF AUTOIMMUNITY

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

(2019) Ivan Perrot et al.   Cell Reports

The role of NK cells and CD39 in the immunological control of tumor metastases

(2019) Haiyan Zhang et al.   OncoImmunology

Clonal replacement of tumor-specific T cells following PD-1 blockade

(2019) Kathryn E. Yost et al.   NATURE MEDICINE

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function

(2019) Selena Vigano et al.   Frontiers in Immunology

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

(2019) Andrea Cossarizza et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

CD103+Tumor-Resident CD8+T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment

(2018) Jarem Edwards et al.   CLINICAL CANCER RESEARCH

CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to Listeria monocytogenes

(2018) Friederike Raczkowski et al.   PLoS One

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

(2018) Thomas Duhen et al.   Nature Communications

Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth

(2018) Ilenia Pacella et al.   Cancer Immunology Research

Wnt3a/β-Catenin Signaling Conditions Differentiation of Partially Exhausted T-effector Cells in Human Cancers

(2018) Valeria Schinzari et al.   Cancer Immunology Research

CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+T Cells—Response

(2018) Fernando P. Canale et al.   CANCER RESEARCH

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

(2018) Yannick Simoni et al.   NATURE

CD39+ regulatory T cells accumulate in colon adenocarcinomas and display markers of increased suppressive function

(2018) Filip Ahlmanner et al.   Oncotarget

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

(2017) Bertrand Allard et al.   IMMUNOLOGICAL REVIEWS

Expansion of activated regulatory T cells inversely correlates with clinical severity in septic neonates

(2016) Eleonora Timperi et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Expression of CD39 on Activated T Cells Impairs their Survival in Older Individuals

(2016) Fengqin Fang et al.   Cell Reports

Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages – a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape

(2016) Itsaso Montalbán del Barrio et al.   Journal for ImmunoTherapy of Cancer

SnapShot: T Cell Exhaustion

(2015) Kristen E. Pauken et al.   CELL

The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation

(2015) Anne Rissiek et al.   JOURNAL OF AUTOIMMUNITY

CD8+CD103+Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients

(2015) Fayçal Djenidi et al.   JOURNAL OF IMMUNOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

CD39 Expression Identifies Terminally Exhausted CD8+ T Cells

(2015) Prakash K. Gupta et al.   PLoS Pathogens

Role of TGF-β Signaling in Generation of CD39+CD73+Myeloid Cells in Tumors

(2014) Sergey V. Ryzhov et al.   JOURNAL OF IMMUNOLOGY

High Expression of Ecto-Nucleotidases CD39 and CD73 in Human Endometrial Tumors

(2014) Elisabet Aliagas et al.   MEDIATORS OF INFLAMMATION

Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

(2014) J. Bastid et al.   Cancer Immunology Research

CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes

(2013) Alessia Parodi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

(2013) Taku Okazaki et al.   NATURE IMMUNOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extracellular adenosine triphosphate and adenosine in cancer

(2010) J Stagg et al.   ONCOGENE

CD39+Foxp3+ Regulatory T Cells Suppress Pathogenic Th17 Cells and Are Impaired in Multiple Sclerosis

(2009) J. M. Fletcher et al.   JOURNAL OF IMMUNOLOGY

CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease

(2009) D. J. Friedman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Differential ectonucleotidase expression in human bladder cancer cell lines

(2009) Joséli Stella et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS